Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
2 hedge funds and large institutions have $514K invested in Checkpoint Therapeutics in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% less ownership
Funds ownership: 0.07% → 0.06% (-0%)
6% less capital invested
Capital invested by funds: $544K → $514K (-$30K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
-$43.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OPPM
1
Opus Point Partners Management
New York
| $507K | -$43.4K | -500 | -4% |
|
|
2
UBS Group
Zurich,
Switzerland
| $7K | -$5.13K | -59 | -42% |
|
CKPT Hedge Fund Activity: Q3 2017 in Review
2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q3 2017, worth a combined $514K — down 5.5% from $544K a quarter earlier.
Fund positioning in CKPT was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Opus Point Partners Management, cutting an estimated $43.4K.
- 2 institutional investors held Checkpoint Therapeutics (CKPT) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $514K of Checkpoint Therapeutics stock for Q3 2017, down 5.5% quarter-over-quarter.
- 0 funds opened new Checkpoint Therapeutics positions in Q3 2017 and 0 closed out.
- The largest Checkpoint Therapeutics seller in Q3 2017 was Opus Point Partners Management, an estimated $43.4K sold.
Based on aggregated 13F filings for Q3 2017.